Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PTGES | O14684 | 3/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128948 | 0.83 | NPC1 (0.64) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL1128947 | 0.80 | ALDH1A1 (0.56) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL18216887 | 0.78 | LMNA (0.56) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL12089386 | 0.77 | MEN1 (0.47) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL2107224 | 0.77 | ALDH1A1 (0.53) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL6433208 | 0.76 | ALDH1A1 (0.64) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL14472457 | 0.75 | MEN1 (0.44) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL14518447 | 0.75 | MEN1 (0.44) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL29036558 | 0.75 | KMT2A (0.50) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL28824749 | 0.75 | KMT2A (0.57) | MEN1KMT2ANPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079877-B2 | Process for preparing chiral compounds | PFIZER INC. (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2185713-B1 | PROCESS FOR PREPARING CHIRAL COMPOUNDS | PFIZER PROD INC (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2532660-B1 | Process for preparing chiral compounds | PFIZER PROD INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20140187794-A1 | Process for Preparing Chiral Compounds | PFIZER INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8642783-B2 | Process for preparing chiral compounds | PFIZER INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2532660-A1 | Synthetic intermediates prepared using a 2-deoxyribose-5-phosphate aldolase (DERA) chemoenzymatic process | Pfizer Products Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20110118476-A1 | Process for Preparing Chiral Compounds | PFIZER INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2185713-A2 | PROCESS FOR PREPARING CHIRAL COMPOUNDS | Pfizer Products Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090221852-A1 | Preparation of an Atorvastatin Intermediate | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009019561-A2 | PROCESS FOR PREPARING CHIRAL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| EP-1922301-A1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE | Pfizer Science and Technology Ireland Limited (IE) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007029217-A1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE | PFIZER SCIENCE AND TECHNOLOGY IRELAND LIMITED (IE) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221852-A1 | Preparation of an Atorvastatin Intermediate | BCKDK, HMGCR, KHK | MEN1 4039/4885KMT2A 2372/4885NPC1 1081/4885 |
| US-20140187794-A1 | Process for Preparing Chiral Compounds | DERA, ALDOA, DPYD | MEN1 2085/4885KMT2A 995/4885NPC1 2455/4885 |
| US-20110118476-A1 | Process for Preparing Chiral Compounds | DERA, ALDOA, DPYD | MEN1 2085/4885KMT2A 995/4885NPC1 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.